A Patient-Oriented Research Program in Geriatric Oncology

项目总结 K24更新提案的首席调查员(PI)Supriya Mohile博士领导了一个独立资助的 罗切斯特大学威尔莫特癌症研究所以病人为导向的老年肿瘤学研究计划。 在过去的K24资助期间，莫希尔博士完成了两项大型多站点随机分组试验， 评估老年评估和管理(GAM)是否改善老年患者的预后 晚期癌症。GAM是一种经过验证的以患者为中心的健康状况评估方法，可识别老年人 有不良后果风险的癌症患者，并指导癌症治疗和 与衰老相关的疾病。这两项试验都首次证明，GAM干预可以改善患者- 以结果为中心(沟通和患者/照顾者满意度)和临床结果(治疗 毒性、跌倒和多药)。罗切斯特大学的学员全面参与了这项研究 并通过癌症和老龄化研究小组(CAPG)利用GAM试验的数据 成功角逐自己的职业发展和自主奖项。十个早期职业生涯中的一个 莫希尔博士目前在罗切斯特大学指导的科学家中，有8名是女性，4名是 在医学界的代表性不足。学员获得了20多份奖助金，并发表了80多篇手稿 和莫希尔医生在一起。莫希尔博士目前是七个职业发展奖的主要导师或共同导师。 此外，在过去的K24资助期间，Mohile博士成功地竞争了三个新的R-Level奖，即PI 从以患者为中心的结果研究和国家卫生研究院评估战略 在肿瘤学实践中实施GAM并扩大对癌症治疗耐受性的了解 上了年纪的人。最初的K24让莫希尔博士和她的学员提高了沟通技能 研究；续订将使他们能够与专家一起学习实施科学和领导力 罗切斯特大学和嘉吉大学的顾问。这项建议的总体目标是：1) 制定和评估GAM在肿瘤学实践中的实施策略；以及2)检查治疗 老年晚期癌症患者开始新的高危癌症的耐受性 治疗方案。这项研究将对语用研究产生积极的影响 在肿瘤护理中实施GAM的机制。重要的是，这项提议将允许职业生涯 开展以患者为中心的老年肿瘤学研究，这是一个研究不足的问题 菲尔德。通过资助的研究，威尔莫特癌症研究所和NIA资助的CAG的捐赠 (MPI：Mohile)，Mohile博士有资源继续促进有兴趣的调查人员的职业生涯 贯穿学术生涯轨迹的老年肿瘤学研究。此次K24大奖的续签将使 Mohile博士将扩大指导，以促进老年肿瘤学中以患者为导向的研究的发展。

PROJECT SUMMARY The principal investigator (PI), Dr. Supriya Mohile, of this K24 renewal proposal leads an independently funded patient-oriented geriatric oncology research program at the University of Rochester Wilmot Cancer Institute. Over the last K24 funding period, Dr. Mohile completed two large multi-site cluster-randomized trials that evaluated whether geriatric assessment and management (GAM) improves outcomes of older patients with advanced cancer. GAM, a validated patient-centered approach for assessing health status, identifies older patients with cancer who are at risk of adverse outcomes and guides management for cancer treatment and for aging-related conditions. Both trials demonstrated, for the first time, that a GAM intervention improves patient- centered outcomes (communication and patient/caregiver satisfaction) and clinical outcomes (treatment toxicity, falls, and polypharmacy). Integrally involved in this research, mentees at the University of Rochester and through the Cancer and Aging Research Group (CARG) have utilized data from the GAM trials to successfully compete for their own career development and independent awards. Of the ten early career scientists that Dr. Mohile currently mentors at the University of Rochester, eight are women and four identify as underrepresented in medicine. Mentees have received over 20 grants and have published over 80 manuscripts with Dr. Mohile. Dr. Mohile is currently a primary mentor or co-mentor on seven career development awards. Further, over the last K24 funding period, Dr. Mohile successfully competed for three new R-level awards as PI from the Patient Centered Outcomes Research and the National Institutes of Health to evaluate strategies for implementing GAM in oncology practices and to expand understanding about cancer treatment tolerability in older adults. The original K24 allowed Dr. Mohile and her mentees to enhance skills in communication research; the renewal will allow them to learn about implementation science and leadership with expert consultants at the University of Rochester and in CARG. The overarching aims of this proposal are: 1) to develop and evaluate implementation strategies for GAM in oncology practices; and 2) to examine treatment tolerability in older patients with advanced cancer and aging-related conditions starting a new high-risk cancer treatment regimen. This research will have a positive impact by providing information on pragmatic mechanisms for implementing GAM in oncology care. Importantly, this proposal will allow for the career development of mentees pursuing patient-oriented research focused on geriatric oncology, an understudied field. Through funded research, an endowment from the Wilmot Cancer Institute, and the NIA-funded CARG (MPI: Mohile), Dr. Mohile has the resources to continue to foster the careers of investigators interested in geriatric oncology research across the academic career trajectory. The renewal of this K24 Award will enable Dr. Mohile to expand mentoring to enhance the growth of patient-oriented research in geriatric oncology.